1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Biopharma IPOs Regain Momentum With Slate Of New Offerings

Four Companies Went Public On 18 March, Raising $678.8m

 
• By Mandy Jackson

Public Company Edition: Instil Bio, Connect Biopharma, Finch Therapeutics, Gain Therapeutics and four heath care-focused SPACs launched initial public offerings; Endo raised $1.3bn via note sale; and Rubius Therapeutics, Solid Biosciences and others priced follow-on offerings.

Finance Watch

Biopharmaceutical companies have launched 26 initial public offerings in the US this year as of the start of the week, including four offerings that priced on 18 March and raised $678.8m for Instil Bio, Inc., Connect Biopharma Holdings Ltd., Finch Therapeutics Group and Gain Therapeutics, Inc.

The IPO market seems to be regaining its momentum after just three drug developers went public in January, followed by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By Mandy Jackson

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 
• By Jessica Merrill

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By Kevin Grogan

Swiss major confident that new oncology drugs will fill revenue gap.